Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression induces carcinogenesis and is thought to be an adverse prognostic factor in gastric carcinomas while the prognostic value of DNA mismatch repair (MMR) is still controversial.
|
27854106 |
2017 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 was expressed in DCAMKL1-positive tuft cells in Cdx2- and DCAMKL1-transgenic mouse stomachs, whereas the Sox9 transcription factor was ubiquitously expressed in gastric carcinomas, including COX-2-positive cells.
|
25228975 |
2014 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Active caspase-3, ssDNA, p53, Bax and COX-2 were more frequently observed among high grade and higher stage (> or =T2) carcinomas compared with low grade and lower stage (T1) tumours.
|
20025478 |
2010 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX2 overexpression has been detected in up to 90% of colon carcinomas, and its downregulation inhibits polyp formation.
|
19468846 |
2009 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C).
|
18094611 |
2008 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By immunohistochemistry, we assessed COX-2 expression in 24 hyperplastic polyps, 7 sessile serrated polyp/adenomas (SSA), 5 mixed polyps with SSA and adenoma, 27 traditional serrated adenomas, 515 non-serrated adenomas (tubular adenoma, tubulovillous adenoma and villous adenoma), 33 adenomas with intramucosal carcinomas, 96 adenocarcinomas with serration (corkscrew gland) and 111 adenocarcinomas without serration.
|
18230181 |
2008 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed a positivity for COX-2 in 72.1% of PIN and in 44.7% of prostate carcinomas with an overexpression of COX-2 in prostate cancer and PIN compared to benign prostatic tissue (P < 0.0005).
|
17265445 |
2007 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, COX-2 mRNA was strongly expressed in the well-differentiated carcinomas compared to those of normal thyroid tissue and follicular adenoma.
|
16362262 |
2006 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data show that the MVD corresponds to the COX-2 overexpression in gallbladder carcinomas.
|
17177652 |
2006 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This suggests that COX-2 over-expression may be an early event in breast cancer aetiology permitting clones within the normal epithelium to evade apoptosis, to increase their numbers and perhaps acquire further changes that promote the formation of hyperplasias, and eventually carcinomas.
|
15642177 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that overexpression of COX-2 is sufficient to cause hyperplasia and carcinomas in the urinary bladder.
|
15753378 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 protein expression was found in all carcinomas under analysis.
|
15958546 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was evaluated through immunohistochemical and mRNA analysis in carcinomas, adenomas, and healthy mucosa from six patients carrying germ line biallelic MYH mutations.
|
16103460 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was found in 12 (92.3%) poorly differentiated carcinomas and in 13 (92.8%) undifferentiated carcinomas.
|
15947945 |
2005 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In nulliparous female mice, aberrant COX-2 overexpression correlated with increased prostaglandin (PG) E(2) levels and caused cystic duct dilatations, adenosis, and fibrosis whereas carcinomas developed rarely.
|
15681840 |
2005 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, PPARgamma protein was not detected in all of the eight carcinomas in which COX-2 protein was detected, suggesting that expression of PPARgamma and COX-2 was in a reciprocal relationship.
|
15266333 |
2004 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
COX-2 gene product was evaluated immunohistochemically in 30 healthy persons, in 22 patients with dysplastic lesions without previous or concomitant carcinomas, and in 29 patients with oral carcinomas.
|
12747975 |
2003 |
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moderate or strong epithelial COX-2 was present in 25% of hamartomas, including two hamartomas with dysplastic changes, and 64% of carcinomas.
|
12912958 |
2003 |
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mRNA copy numbers for COX-2 were determined in 18 infiltrating carcinomas using quantitative RT-PCR and TaqMan methodology.
|
12740157 |
2003 |
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We investigated 5 gastric cancer cell lines and 58 primary gastric carcinomas for the presence of promoter hypermethylation in cox-2 gene.
|
12684668 |
2003 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Such directed apoptosis could eventually serve as a treatment for an entire class of Cox-2-overexpressing carcinomas.
|
12900768 |
2003 |
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
COX-2 staining was more intense in the carcinomas compared with normal epithelium (P < 0.001).
|
12738747 |
2003 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of COX-2 was detected in 23 (82%) of 28 PJPs and in all carcinomas.
|
14623934 |
2003 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was comparable in gastric stump carcinomas and conventional gastric carcinomas and localized primarily to the cytoplasm of the neoplastic cells.
|
11793368 |
2002 |
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of COX-2 and synthesis of PGE2 are up-regulated in cervical carcinomas.
|
12468638 |
2002 |